Detail akcie Lakefront Biotherapeutics online

Business Summary: Lakefront Biotherapeutics NV is a Belgium-based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal-making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical-stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in-house cell therapy platforms. It builds a portfolio of clinical-stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Lakefront Biotherapeutics NV revenues decreased 91% to EUR6.5M. Net income before extraordinary items totaled EUR13.9M vs. loss of EUR154.6M. Revenues reflect Collaboration revenues decrease of 97% to EUR1.6M, Supply revenues decrease of 64% to EUR4.9M. Net Income reflects Research and development expenses decrease of 83% to EUR31M (expense).